Klivira
Request demo

Streamlining Medicare Tepezza Prior Authorization for Thyroid Eye Disease

Successfully managing Medicare Tepezza prior authorization is critical for timely patient access to this essential therapy for Thyroid Eye Disease (TED). Klivira simplifies the complex pathways for teprotumumab approvals.

Tepezza (teprotumumab) is a high-cost biologic, making prior authorization a frequent requirement across all payer types, including Medicare. For revenue cycle directors and prior authorization coordinators, understanding the nuances of Medicare's specific requirements—from Original Medicare's limited scope to Medicare Advantage plans' more extensive protocols—is key to minimizing delays and denials.

Tepezza: Indication and Coverage Considerations for Medicare

Tepezza (teprotumumab) is an insulin-like growth factor-1 receptor (IGF-1R) inhibitor indicated for the treatment of Thyroid Eye Disease (TED). As a specialized infusion therapy, Tepezza typically falls under the medical benefit (Medicare Part B) for Original Medicare beneficiaries, while Medicare Advantage (Part C) plans administer benefits through their own contracted networks and formularies. The high cost and specialized nature of teprotumumab necessitate rigorous medical necessity review.

Navigating Prior Authorization for Tepezza in Original Medicare

For Original Medicare (Fee-for-Service) members, where prior authorization is required for specific services, submissions for Tepezza would route through the responsible Medicare Administrative Contractor (MAC) for the provider's jurisdiction. While Original Medicare has a limited PA scope, high-cost therapies like Tepezza often trigger review. Klivira's MAC-aware routing addresses the per-jurisdiction submission specifics for contractors such as Noridian, NGS, WPS, Palmetto, FCSO, and Novitas.

Prior Authorization for Tepezza with Medicare Advantage Plans

Medicare Advantage (MA) plans, operated by private insurers, typically have more extensive prior authorization requirements for specialty drugs like Tepezza compared to Original Medicare. These plans adhere to CMS guidelines but often implement their own specific medical policies, formularies, and utilization management criteria, including step therapy or quantity limits. The recent CMS-0057-F rule primarily affects MA plans, aiming to streamline PA processes and improve transparency for these beneficiaries.

Essential Documentation and Policy Adherence for Tepezza PA

Successful Tepezza prior authorization under Medicare hinges on comprehensive clinical documentation that substantiates medical necessity for Thyroid Eye Disease. For Original Medicare, this involves aligning with National Coverage Determinations (NCDs) published by CMS and Local Coverage Determinations (LCDs) issued by the relevant MAC for your jurisdiction. Documentation should clearly articulate diagnosis, disease activity, and previous treatment history in accordance with these published policies.

Klivira's Role in Automating Tepezza Prior Authorization for Medicare

Klivira integrates with your EMR to automate the submission of Tepezza prior authorizations across both Original Medicare and Medicare Advantage plans. For Original Medicare, our platform facilitates routing through MAC-jurisdiction specific channels, incorporating NCD/LCD-aware policy logic. For Medicare Advantage, Klivira connects directly with payer portals and ePA channels, reducing manual data entry and accelerating the approval process for teprotumumab.

Frequently asked questions

Does Original Medicare always require prior authorization for Tepezza?

Original Medicare's prior authorization scope is generally limited. However, for high-cost, specialized therapies like Tepezza (teprotumumab), medical necessity review is common. The specific requirements depend on the service and the policies of your regional Medicare Administrative Contractor (MAC).

How do Medicare Advantage plans handle Tepezza prior authorization differently?

Medicare Advantage (MA) plans, being private insurance, typically have more comprehensive prior authorization requirements than Original Medicare. They establish their own formularies, medical policies, and utilization management criteria for Tepezza, which may include step therapy or quantity limits, all while adhering to broader CMS guidelines.

What documentation is crucial for Tepezza prior authorization under Medicare?

Key documentation for Tepezza prior authorization includes a confirmed diagnosis of Thyroid Eye Disease (TED), detailed clinical notes on disease activity, objective measures of disease progression, and the patient's treatment history. For Original Medicare, alignment with relevant National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs) is essential.

Which Medicare entities process Tepezza prior authorizations?

For Original Medicare, prior authorizations for Tepezza (as a Part B medical benefit) are processed by the specific Medicare Administrative Contractor (MAC) responsible for your geographic region. For Medicare Advantage plans, the prior authorization is handled by the private insurance company administering the specific MA plan.

Can Klivira integrate with my EMR for Tepezza prior authorizations?

Yes, Klivira is designed to integrate seamlessly with major EMR systems using standards like SMART on FHIR. This integration allows for automated data extraction and submission for Tepezza prior authorizations, reducing manual effort and improving accuracy for both Original Medicare and Medicare Advantage submissions.

Related coverage

Other tepezza prior authorization by payer

Other tepezza prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo